Trader consensus for no hantavirus vaccine approval or licensure by the end of 2026 reflects the early development stage of candidates, with most mRNA and DNA platforms still in preclinical animal testing or Phase 1 safety trials as of September 2026. Recent progress includes promising single-dose mRNA results in hamster models against Andes virus and ongoing optimization by groups like Korea University-Moderna and UTMB, yet no Phase 3 efficacy studies are underway for any strain. Hantavirus diversity across regions further complicates broad protection. While an outbreak on the MV Hondius cruise ship heightened visibility and spurred some funding discussions, standard regulatory and manufacturing timelines make 2026 licensure improbable absent an unprecedented acceleration akin to Operation Warp Speed.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhậtHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% khả năng
$131,791 KL.
$131,791 KL.
Dec 31, 2026
6% khả năng
$131,791 KL.
$131,791 KL.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus for no hantavirus vaccine approval or licensure by the end of 2026 reflects the early development stage of candidates, with most mRNA and DNA platforms still in preclinical animal testing or Phase 1 safety trials as of September 2026. Recent progress includes promising single-dose mRNA results in hamster models against Andes virus and ongoing optimization by groups like Korea University-Moderna and UTMB, yet no Phase 3 efficacy studies are underway for any strain. Hantavirus diversity across regions further complicates broad protection. While an outbreak on the MV Hondius cruise ship heightened visibility and spurred some funding discussions, standard regulatory and manufacturing timelines make 2026 licensure improbable absent an unprecedented acceleration akin to Operation Warp Speed.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Thị trường mở: May 4, 2026, 10:39 AM ET
Khối lượng
$131,791Ngày kết thúc
Jan 1, 2027Thị trường mở
May 4, 2026, 10:39 AM ETNgười giải quyết
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus for no hantavirus vaccine approval or licensure by the end of 2026 reflects the early development stage of candidates, with most mRNA and DNA platforms still in preclinical animal testing or Phase 1 safety trials as of September 2026. Recent progress includes promising single-dose mRNA results in hamster models against Andes virus and ongoing optimization by groups like Korea University-Moderna and UTMB, yet no Phase 3 efficacy studies are underway for any strain. Hantavirus diversity across regions further complicates broad protection. While an outbreak on the MV Hondius cruise ship heightened visibility and spurred some funding discussions, standard regulatory and manufacturing timelines make 2026 licensure improbable absent an unprecedented acceleration akin to Operation Warp Speed.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Khối lượng
$131,791Ngày kết thúc
Jan 1, 2027Thị trường mở
May 4, 2026, 10:39 AM ETNgười giải quyết
0x65070BE91...Trader consensus for no hantavirus vaccine approval or licensure by the end of 2026 reflects the early development stage of candidates, with most mRNA and DNA platforms still in preclinical animal testing or Phase 1 safety trials as of September 2026. Recent progress includes promising single-dose mRNA results in hamster models against Andes virus and ongoing optimization by groups like Korea University-Moderna and UTMB, yet no Phase 3 efficacy studies are underway for any strain. Hantavirus diversity across regions further complicates broad protection. While an outbreak on the MV Hondius cruise ship heightened visibility and spurred some funding discussions, standard regulatory and manufacturing timelines make 2026 licensure improbable absent an unprecedented acceleration akin to Operation Warp Speed.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp